MarketPulse

GLP-1 market

4 articles
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Market Dominance vs. Viking's Promise: Weight Loss Drug Showdown

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.
LLYNVOVKTXclinical trialsmarket share
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk Stock Looks Cheap, But Execution Risks Cloud Recovery Outlook

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.
LLYNVOweight loss drugspharmaceutical competition
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk's Obesity Drug Underperforms Rival Zepbound in Late-Stage Trial

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.
LLYNVOclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Therapeutics Market Poised to Exceed $33B by 2030 on Formulation Innovation

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.
PFELLYNVOAZNpersonalized medicinediabetes treatment